ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Small Increased Risk for CIN & Cervical CA with TNF Inhibitors

Laura Newman  |  January 21, 2016

NEW YORK (Reuters Health)—Women with rheumatoid arthritis (RA) are at increased risk for cervical intraepithelial neoplasia (CIN), and those taking a tumor necrosis factor (TNF) inhibitor are at increased risk of cervical cancer, according to a study from Sweden. “Whether this (the increase in invasive cancers) was due to the TNF inhibitors, disease severity, or…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Cancercervical cancerRheumatoid Arthritis (RA)TNFTNF inhibitorstumor necrosis factorWomen

Ethics Forum: Physicians Face Ethical Quandary Discussing Poor Prognosis with Patients

Rashmi Shah, MD, Jennifer Barton, MD, & Robert H. Shmerling, MD  |  January 19, 2016

Over the course of a month, you diagnose systemic sclerosis in two newly evaluated patients. Their responses to the news could not be more different. Patient 1 is a previously healthy 55-year-old man who is an avid bicyclist and skier. He presents with a several-month history of rapidly progressive skin tightening extending to the proximal…

Filed under:EthicsPractice SupportProfessional Topics Tagged with:Ethicspatient communicationphysicianprognosis

Pattern Recognition Key to Fibrosing Lung Disease Diagnosis

Mary Beth Nierengarten  |  January 19, 2016

SAN FRANCISCO—“Interstitial lung disease is the last bastion of great medicine,” according to Paul Noble, MD, chair, Department of Medicine, director, Women’s Guild Lung Institute, Vera and Paul Guerin Distinguished Chair in Pulmonary Medicine, Cedars-Sinai Medical Center, Los Angeles. Making it great medicine, he said, are the many things still unknown about this disease. In…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:AC&RAmerican College of Rheumatology (ACR)Diagnosisfibrosing lung diseaseResearchrheumatology

Pharmaceutical Care Models, Tools for Treating Patients with Rheumatoid Arthritis

Louise Grech, BPharm (Hons), MPhil, MRPharmS, Victor Ferrito, BSc, MSc, PhD, CSci, Liberato Camilleri, BEd, MSc, PhD, Anthony Serracino Inglott, BPharm, PharmD, MRPharmS, & Lilian M. Azzopardi, BPharm (Hons), MPhil, PhD, MRPharmS  |  January 19, 2016

Rheumatoid arthritis (RA) can be defined as a chronic autoimmune systemic inflammatory condition characterized by symmetrical polyarthritis. Typically, patients present with pain, stiffness and warmth of the affected joints. The condition can result in extra-articular features, adding to disability, and may eventually lead to premature death, especially if not treated early and appropriately.1,2 Over the…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Drugspatient carepharmaceuticalRheumatoid arthritistherapyTreatment

Medicare Drug Coverage Plans for Rheumatologic Medications

From the College  |  January 19, 2016

Different parts of Medicare cover different services. For outpatient prescription drugs, Medicare has two distinct programs with a maze of complex policies. Most physicians along with Medicare patients, retail pharmacies, Medicare drug plans as well as Medicare Advantage health plans continuously struggle with navigating Medicare drug coverage under Part B and Part D. There are…

Filed under:From the College Tagged with:Centers for Medicare & Medicaid Services (CMS)costscoverageDrugsMedicarerheumatology

Gene Manipulation Has Potential to Alter Genomes, Impact Society

Gene Manipulation Has Potential to Alter Genomes, Impact Society

Simon M. Helfgott, MD  |  January 19, 2016

Every so often, a major scientific breakthrough profoundly alters the trajectory of scientific research. In the 1960s, microbiologists sparked the recombinant-DNA revolution with the discovery that bacteria have innate immune systems based on restriction enzymes. These enzymes bind and cut invading viral genomes at specific short sequences, and scientists rapidly repurposed them to cut and…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:discoverygenegenomeimpactpublic healthscience

Pfizer Hikes U.S. Prices for More Than 100 Drugs on Jan. 1

Deena Beasley  |  January 12, 2016

(Reuters)—Pfizer Inc., which plans a $160-billion merger with Ireland-based Allergan Plc to slash its U.S. tax bill, on Jan. 1 raised U.S. prices for more than 100 of its drugs, some by as much as 20%, according to statistics compiled by global information services company Wolters Kluwer. Pfizer confirmed a 9.4% increase for heavily advertised…

Filed under:Drug Updates Tagged with:costsDrugsPfizer Inc.

Novartis Signs $170 Million Immuno-Oncology Pact with Surface

John Miller  |  January 12, 2016

ZURICH (Reuters)—Novartis AG has struck a $170 million alliance with U.S.-based Surface Oncology as it seeks to boost its portfolio of medicines that help the body’s immune system fight cancer. The accord, which it announced on Monday, gives Novartis access to four pre-clinical programs aiming to help prevent tumors from evading the immune system, including…

Filed under:Drug Updates Tagged with:Cancerimmune responseImmune SystemImmuno-OncologyNovartisT cell

Study Uncovers Tet2’s Role in Resolving Inflammation

Lara C. Pullen, PhD  |  January 11, 2016

When investigating the role of epigenetic modifiers in inflammatory response, researchers found that Tet2 acts at the chromatin level to help resolve inflammation in both dendritic cells and macrophage, repressing the transcription of IL-6…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:DNAinflammationTET proteinTet2

NIH-Funded Trials Dip While Industry Trials Are on the Rise

Kathryn Doyle  |  December 17, 2015

(Reuters Health)—Every year since 2006 in the U.S., the number of clinical trials funded by the National Institutes of Health (NIH) has gone down, while the number of industry-funded trials has gone up, a new study shows. Analyzing the ClinicalTrials.gov database, researchers found that after trial registration became a requirement for publication in major scientific…

Filed under:Drug Updates Tagged with:clinical trialsDrugsNational Institutes of Health (NIH)pharmaceutical companyPharmaceutical Research

  • « Previous Page
  • 1
  • …
  • 58
  • 59
  • 60
  • 61
  • 62
  • …
  • 86
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences